Home > Boards > US Listed > Biotechs > GX Acquisition Corp (GXGX)

Celularity Inc has closed the merger with GX

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 705
Posts 47,345
Boards Moderated 5
Alias Born 12/12/04
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/17/2021 2:49:46 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/17/2021 2:44:52 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 9/17/2021 8:38:14 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/15/2021 6:50:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/15/2021 4:50:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2021 6:19:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2021 6:14:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2021 6:12:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2021 6:07:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2021 6:05:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2021 6:04:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2021 6:02:02 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2021 5:59:00 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/20/2021 6:05:04 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 8/20/2021 6:04:08 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/20/2021 6:03:33 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/20/2021 6:03:27 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/19/2021 6:05:07 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/16/2021 5:29:30 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/12/2021 4:23:54 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 8/3/2021 6:41:47 PM
Sec Staff Action/letter (sec Staff) Edgar (US Regulatory) - 7/27/2021 10:01:50 AM
Sec Staff Action/letter (sec Staff) Edgar (US Regulatory) - 7/27/2021 10:00:29 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/26/2021 7:33:18 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/26/2021 5:50:09 PM
crudeoil24 Member Level  Friday, 07/16/21 12:48:04 PM
Re: crudeoil24 post# 4
Post # of 6 
Celularity Inc has closed the merger with GX Acquisition Corp (NASDAQ: GXGX), giving Celularity $138 million to push the NK cell and T cell therapies into early-stage trials.
The combined company will operate under the name Celularity Inc (NASDAQ: CELU), and its common stock will commence trading on the NASDAQ from Monday (19 July) under the ticker symbol CELU.
The company expanded its ongoing Phase 1 trial of CYNK-001 in patients with acute myeloid leukemia (AML)to include patients with relapsed/refractory AML (r/r AML) in addition to its ongoing trial in measurable residual disease (MRD).
To date, no dose-limiting toxicity was observed with outpatient administration of three doses.
The FDA granted Orphan Drug Designation to CYNK-001 for the treatment of patients with malignant gliomas.
CYNK-001 is currently in a Phase 1 trial for glioblastoma multiforme.
For Phase 1/2 COVID-19 trial assessing CYNK-001, no evidence of dose-limiting toxicities or evidence of no worsening inflammatory biomarkers was observed, and enrollment is ongoing.

New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences